Heron Gains on Priority Review Designation for Pain Drug
Shares of Heron Therapeutics, Inc. HRTX rose 9.22% on Dec 31 after the company announced that the FDA has accepted the new drug application (NDA) for experimental candidate, HTX-011, which was submitted to the agency on Oct 30, 2018. […]